LX-2931

DB06297InvestigationalSmall molecule

Investigated for use/treatment in rheumatoid arthritis, inflammatory disorders (unspecified), and autoimmune diseases.

Chemical structure of LX-2931
Primary indication
Investigated for use/treatment in rheumatoid arthritis, inflammatory disorders (unspecified), and autoimmune diseases.Curator reviewed
Formula / weight
C9H15N3O5 · 245.235 g/mol (avg)
Code names
LX 2931 · LX-3305

Resolves to

Compound
UNIIC5AGI979T7CAS948840-25-3ChEMBLCHEMBL1852164
Structure
InChIKeyAMXVYJYMZLDINS-RSWLNLDNSA-NSMILESC\C(=N/O)C1=NC=C(N1)[C@@H](O)[C@H](O)[C@H](O)CO
Targets
O95470SGPL1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with LX-2931, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In